Clinical trial
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
NCT01833923 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- October 31, 2015
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cancer